Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Myriad Genetics settles with BRCA test competitors

02 February 2015

By Cait McDonagh

Appeared in BioNews 788

Myriad Genetics has settled litigation with competitors who had been using genetic testing for breast cancer genes. The molecular diagnostics company agreed with a number of companies not to proceed with claims for patent infringement in return for ceasing any outstanding counterclaims. It is in the process of reaching a settlement with those that are remaining.

Myriad was attempting to defend patents on genetic testing for the BRCA1 and BRCA2 genes, associated with hereditary breast and ovarian cancer. The US Supreme Court ruled in 2013 that human genes were products of nature and could not be patented, invalidating some of Myriad's patent claims. However, the company attempted to enforce other patents against six competitors offering or about to offer genetic tests for BRCA1 and BRCA2 gene mutations, including LabCorp, Invitae and Ambry Genetics. A number of these companies responded by issuing counter-claims against Myriad.

In December 2014 the US Court of Appeals for the Federal Circuit upheld an earlier decision to deny Myriad an injunction what would have prevented Ambry from selling the test. Since then, Myriad has approached other parties about settling the claims, including agreements not to start fresh claims under other existing patents.

Ronald Rogers, spokesman for the company, said that after December's ruling 'we decided it was in the best interest of the company to settle these matters'.

Myriad is developing new types of test to reduce its reliance on the BCRA test, including a more comprehensive test of 25 genes linked to cancer risk.

SOURCES & REFERENCES
ScienceInsider | 28 January 2015
 
Pathway Genomics (press release) | 23 January 2015
 
New York Times | 27 January 2015
 
GenomeWeb | 26 January 2015
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

23 May 2016 - by Antony Blackburn-Starza 
Myriad Genetics has been hit by a complaint filed by the American Civil Liberties Union (ACLU) on behalf of four patients who are seeking a right of access to all their genetic information held by the company...
14 March 2016 - by Ryan Ross 
Tania Simoncelli's narrates the story of the successful legal challenge against Myriad Genetics' BRCA patents, but may have missed an opportunity to consider the broader impact of gene patenting...
12 October 2015 - by Cait McDonagh 
An isolated gene sequence cannot be patented, Australia's highest court has unanimously ruled. It is the latest and final decision in litigation that has lasted over five years...
22 June 2015 - by Paul Waldron 
Australia's highest court will decide whether isolated molecules of DNA linked to a gene mutation associated with an increased risk of hereditary breast and ovarian cancers are patentable under Australian law....
27 April 2015 - by Dr Indrayani Ghangrekar 
A US company has announced a low-cost genetic test for breast cancer...

08 September 2014 - by Matthew Thomas 
Gene sequences isolated from the human body are patentable, according to a ruling by the Australian federal court...
23 June 2014 - by Alice Plein 
Pathway Genomics, a biotech company based in San Diego, announced it will 'vigorously defend itself' against a patent infringement suit filed by Myriad Genetics and others...
17 March 2014 - by Patricia Cassidy 
Myriad Genetics has failed to obtain a preliminary injunction to prevent a competitor, Ambry Genetics, from offering BRCA-related genetic testing products...
15 July 2013 - by Ruth Retassie 
Myriad Genetics is suing two other companies who are offering genetic tests for BRCA1 and BRAC2 gene mutations for patent infringement...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation